U.S. Stock News

Annexon (ANNX) is back in focus after a busy August, with a key update to its Phase 3 ARCHER II trial for vonaprument, fresh Guillain-Barré data, Q2 earnings, and a boardroom change drawing investor attention. See our latest analysis for Annexon. Over the past year Annexon has shifted from a relatively muted share price pattern to strong momentum, with a 12.79% year to date share price return and a very large 1 year total shareholder return of 116.80%, even though the 5 year total shareholder...

Adeia Inc. recently reported its second-quarter 2026 results, with sales of US$96.12 million and net income of US$17.37 million, declared a US$0.05 per-share dividend, reiterated full-year 2026 revenue guidance of US$395.00–US$435.00 million and net income of US$57.20–US$80.40 million, and confirmed progress on its multi-year share repurchase program. The combination of higher year-on-year sales and net income, continued dividend payments, and ongoing buybacks highlights Adeia’s focus on...

Lindblad Expeditions Holdings recently reported second-quarter 2026 results, with sales rising to US$199.25 million and quarterly net loss shrinking to US$1.41 million, alongside first-half 2026 net income of US$5.09 million. The company also issued full-year 2026 tour revenue guidance of US$830 million to US$860 million, giving investors a clearer view of expected business activity. We’ll now examine how the new full-year revenue guidance and improving first-half profitability could reshape...

Kodiak Sciences reported second-quarter 2026 results showing a wider net loss of US$65.64 million and basic loss per share of US$1.05, reflecting increased spending as its clinical pipeline advances. Alongside the earnings, Kodiak completed enrollment of the first 300-patient cohort in its PEAK Phase 3 trial of KSI-101 for macular edema secondary to inflammation, marking an important milestone for this bispecific IL-6 and VEGF inhibitor program. We’ll now examine what Kodiak’s increased...

Amazon.com (NasdaqGS:AMZN) is reported to be a leading bidder for AI company Decart AI in an ongoing sale process. Decart AI has also drawn interest from tech companies including SpaceX and Nebius after NVIDIA exited acquisition talks. The bidding highlights intense competition among large tech groups to secure AI talent, models and infrastructure. For more context on how other companies are building AI infrastructure, consider reviewing a broader set of related stocks through 55 AI...

Provident Financial Services, Inc. and Provident Bank recently expanded their boards to 13 directors, electing veteran FDIC regulator Michael E. Regan as a Class of 2028 director and appointing Diane Gigliotti as Chief Accounting Officer to oversee accounting policy, financial and regulatory reporting, and internal controls. These appointments add deep regulatory oversight and technical accounting expertise at board and executive levels, potentially tightening governance, risk management,...

In August 2026, QIAGEN received U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, expanding its QIAstat-Dx platform into bloodstream infection diagnostics by enabling one-hour detection of multiple pathogens and antimicrobial resistance markers from positive blood culture samples. This move not only broadens QIAGEN’s infectious disease testing menu across four major syndromic areas on a single platform, it also supports faster, more targeted sepsis care in a country where an...

Roivant Sciences Ltd. reported first-quarter 2026 results for the period ended June 30, 2026, with sales of US$1.44 million versus US$2.17 million a year earlier and a net loss of US$189.84 million compared with US$223.36 million, while basic loss per share from continuing operations narrowed to US$0.26 from US$0.33. The combination of lower revenue but a smaller net loss points to tighter cost control or operating efficiencies that may influence how investors assess the company’s progress...

Pelagos Insurance Capital (PLGO) drew fresh attention after reporting second quarter 2026 results, with revenue of US$650 million and net income of US$44.4 million, alongside a swing to profit for the first half. See our latest analysis for Pelagos Insurance Capital. The earnings swing back to profit and the recently affirmed US$0.15 per share dividend come against a mixed price backdrop. Pelagos Insurance Capital’s 1 day share price return of 4.79% contrasts with a 30 day share price return...

MediWound Ltd. ( NASDAQ:MDWD ) defied analyst predictions to release its quarterly results, which were ahead of market...

One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...

Investors who take an interest in Quanterix Corporation ( NASDAQ:QTRX ) should definitely note that the Executive...

Medtronic (MDT) is under renewed scrutiny after a federal jury ordered the company to pay US$88 million in compensatory damages tied to hernia mesh products from its Covidien unit, with Medtronic planning to challenge the verdict. See our latest analysis for Medtronic. Despite the legal setback, Medtronic’s recent share price performance has improved, with a 4.72% 7 day share price return and 18.04% 90 day share price return. The 1 year total shareholder return of 1.31% points to more muted...

Bending Spoons S.p.A. recently reported second-quarter 2026 results, with sales rising to US$704.16 million and net income reaching US$176.97 million, alongside upgraded revenue guidance for the third quarter and full year 2026. The company’s shift from a net loss in the prior-year six-month period to a US$204.43 million profit underscores how its acquisition-driven model is now translating into materially higher earnings and cash-generating capacity. We’ll now examine how this sharp swing...

AbbVie (NYSE:ABBV) and Genmab reported that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in diffuse large B-cell lymphoma did not meet its overall survival primary endpoint. Epcoritamab retains its current accelerated FDA approval, but the Phase 3 outcome raises regulatory and commercial uncertainty for the oncology asset. The setback comes alongside other recent AbbVie product news, including FDA acceptance of a new BOTOX Cosmetic application and progress on Canadian reimbursement for...

InvenTrust Properties Corp. reported past second-quarter 2026 results showing sales of US$82.34 million and revenue of US$82.83 million, both higher than a year earlier, while net income fell sharply to US$1.37 million and diluted EPS from continuing operations dropped to US$0.02. Despite the weaker profitability, management raised full-year 2026 net income guidance per diluted share to a range of US$0.12–US$0.18 and highlighted an active acquisition pipeline funded by capital recycling from...

Unity Software earnings event and why it matters now Unity Software (U) has drawn fresh attention after its second quarter 2026 earnings, with sales of US$546.47 million and a reduced net loss of US$23.61 million compared with a year earlier. See our latest analysis for Unity Software. Unity Software’s recent Q2 update, including rapid uptake of its Vector AI-powered ad platform, has arrived alongside strong momentum, with a 30-day share price return of 59.54% and a 1-year total shareholder...

Independence Realty Trust (IRT) has just reported its second quarter and first half 2026 results, alongside reaffirmed full year earnings guidance. This gives investors fresh data on both recent performance and management expectations. See our latest analysis for Independence Realty Trust. Over the past year, Independence Realty Trust has seen mixed momentum, with a 4.74% 90 day share price return and a 1.92% total shareholder return over 12 months. The year to date share price return is down...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Southside...

US tariffs on Vietnam have quietly shifted, and that change is already reshaping where companies source everything from T shirts to steel coils. Higher duties and tougher compliance can squeeze import heavy business models, while producers closer to home may see fresh interest. This article walks through 3 stocks that screen as potential beneficiaries of this onshoring trend so you can judge whether any deserve a closer look. These three stocks are only a starting sample, and the full screen...

Earlier this month, Amplitude, Inc. reported second-quarter 2026 results, with sales rising to US$100.89 million while net loss widened to US$34.62 million, and the company subsequently presented at the KeyBanc Technology Leadership Forum in Park City, Utah. The company also lifted its full-year 2026 revenue guidance to a range of US$407.2 million to US$411.2 million, highlighting growing customer engagement with its AI-driven analytics platform and the expanded offering following the...

Tarsus Pharmaceuticals, Inc. reported past second-quarter 2026 results showing revenue of US$173.91 million versus US$102.66 million a year earlier, with net loss narrowing to US$18.55 million and loss per share from continuing operations improving to US$0.43. Alongside these results, the company raised its 2026 XDEMVY net product sales guidance to a higher US$685 million–US$705 million range, signaling management’s increased confidence in the product’s commercial trajectory. We’ll now...

Brookdale Senior Living earnings jump to profit despite lower revenue Brookdale Senior Living (BKD) reported second quarter 2026 results on 10 August, shifting from a net loss a year ago to a net profit, even as sales and total revenue were lower. See our latest analysis for Brookdale Senior Living. Brookdale Senior Living's recent earnings swing to profit comes as the share price has eased in the short term, with a 7 day share price return of an 11.11% decline and a 30 day share price...

Manhattan Associates (MANH) continues to attract attention after recent share price moves, with the stock last closing at $197.39. Investors are weighing this performance against the company’s current fundamentals and valuation signals. See our latest analysis for Manhattan Associates. The recent 20.96% 1 month share price return and 44.39% 3 month share price return suggest momentum is building in Manhattan Associates, even though the 1 year total shareholder return is down 8.10%. If you are...